Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment

European Journal of Cardio-thoracic Surgery

Volumn 31, Issue 5, 2007, Pages 773-779

  Opitz, Isabelle ^a   Lardinois, Didier ^a   Arni, Stephan ^a   Hillinger, Sven ^a   Vogt, Peter ^a   Odermatt, Bernhard ^a   Rousson, Valentin ^b   Weder, Walter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Animal model; Cisplatin; Extrapleural pneumonectomy; Intrapleural; Mesothelioma; Recurrence

Indexed keywords

CISPLATIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; POVIDONE IODINE; SEALANT; SODIUM CHLORIDE; TAUROLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CONTROLLED STUDY; HISTOPATHOLOGY; MALE; MALIGNANT MESOTHELIOMA; MODEL; NONHUMAN; PLEURA CANCER; PRIORITY JOURNAL; RAT; THORACOTOMY; TUMOR VOLUME;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMOKINES, CC; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FIBRIN TISSUE ADHESIVE; MALE; MESOTHELIOMA; NEOPLASM RECURRENCE, LOCAL; PLEURAL NEOPLASMS; PNEUMONECTOMY; POVIDONE-IODINE; RATS; RATS, INBRED F344; TAURINE; THIADIAZINES;

EID: 34047099357     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2007.01.047     Document Type: Article

References (25)

1. Robinson B.W.S., and Lake R.A. Advances in malignant mesothelioma. N Engl J Med 353 15 (2005) 1591-1603
2. Weder W., Kestenholz P., Taverna C., Bodis S., Lardinois D., Jerman M., and Stahel R.A. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22 17 (2004) 3451-3457
3. Richards W.G., Zellos L., Bueno R., Jaklitsch M.T., Janne P.A., Chirieac L.R., Yeap B.Y., Dekkers R.J., Hartigan P.M., Capalbo L., and Sugarbaker D.J. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 24 10 (2006) 1561-1567
4. Rusch V., Saltz L., Venkatraman E., Ginsberg R., McCormack P., Burt M., Markman M., and Kelsen D. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12 6 (1994) 1156-1162
5. Monnet I., Breau J.-L., Moro D., Lena H., Eymard J.-C., Menard O., Vuillez J.-P., Chokri M., Romet-Lemonne J.-L., and Lopez M. Intrapleural infusion of activated macrophages and {gamma}-interferon in malignant pleural mesothelioma*: a phase II study. Chest 121 6 (2002) 1921-1927
6. Sterman D.H., Recio A., Vachani A., Sun J., Cheung L., DeLong P., Amin K.M., Litzky L.A., Wilson J.M., Kaiser L.R., and Albelda S.M. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 11 20 (2005) 7444-7453
7. Lardinois D., Jung F.J., Opitz I., Rentsch K., Latkoczy C., Vuong V., Varga Z., Rousson V., Gunther D., and Bodis S. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J Thorac Cardiovasc Surg 131 3 (2006) 697
8. Kucharczuk J.C., Elshami A.A., Zhang H.B., Smythe W.R., Hwang H.C., Tomlinson J.S., Amin K.M., Litzky L.A., Albelda S.M., and Kaiser L.R. Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer. Ann Thorac Surg 60 3 (1995) 593-597
9. Hillinger S., Yang S.-C., Zhu L., Huang M., Duckett R., Atianzar K., Batra R.K., Strieter R.M., Dubinett S.M., and Sharma S. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-{gamma}-dependent antitumor responses in a lung cancer model. J Immunol 171 12 (2003) 6457-6465
10. Craighead J.E., Akley N.J., Gould L.B., and Libbus B.L. Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 129 3 (1987) 448-462
11. Coligan J.E., Bierer B.E., Margulies D.H., Shevach E.M., and Strober W. Curr Protocols Immunol (2006), John Wiley and Sons, New York
12. Phillips R., and Ager A. Activation of pertussis toxin-sensitive CXCL12 (SDF-1) receptors mediates transendothelial migration of T lymphocytes across lymph node high endothelial cells. Eur J Immunol 32 3 (2002) 837-847
13. Prewitt T.W., Lubensky I.A., Pogrebniak H.W., and Pass H.I. Orthotopic implantation of mesothelioma in the pneumonectomized immune-deficient rat: a model for innovative therapies. Int J Cancer 55 5 (1993) 877-880
14. Kane A.B. Animal models of malignant mesothelioma. Inhal Toxicol 18 12 (2006) 1001-1004
15. de Bree E., van Ruth S., Baas P., Rutgers E.J.T., van Zandwijk N., Witkamp A.J., and Zoetmulder F.A.N. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 121 2 (2002) 480-487
16. Lu C., Perez-Soler R., Piperdi B., Walsh G.L., Swisher S.G., Smythe W.R., Shin H.J., Ro J.Y., Feng L., Truong M., Yalamanchili A., Lopez-Berestein G., Hong W.K., Khokhar A.R., and Shin D.M. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 23 15 (2005) 3495-3501
17. Opitz I., Kestenholz P., Lardinois D., Muller M., Rousson V., Schneiter D., Stahel R., and Weder W. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 29 4 (2006) 579
18. Jacobi C.A., Menenakos C., and Braumann C. Taurolidine-a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 16 9 (2005) 917-921
19. Opitz I., Ven Der Veen H.C., Braumann C., Ablassmaier B., Fuhrer K., and Jacobi C.A. The influence of adhesion prophylactic substances and taurolidine/heparin on local recurrence and intraperitoneal tumor growth after laparoscopic-assisted bowel resection of colon carcinoma in a rat model. Surg Endosc 17 7 (2003) 1098-1104
20. Calabresi P., Goulette F.A., and Darnowski J.W. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 61 18 (2001) 6816-6821
21. Jacobi C.A., Wenger F., Sabat R., Volk T., Ordemann J., and Muller J.M. The impact of laparoscopy with carbon dioxide versus helium on immunologic function and tumor growth in a rat model. Dig Surg 15 2 (1998) 110-116
22. Lanfrancone L., Boraschi D., Ghiara P., Falini B., Grignani F., Peri G., Mantovani A., and Pelicci P.G. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1. Blood 80 11 (1992) 2835-2842
23. Bielefeldt-Ohmann H., Jarnicki A.G., and Fitzpatrick D.R. Molecular pathobiology and immunology of malignant mesothelioma. J Pathol 178 4 (1996) 369-378
24. Schmitter D., Lauber B., Fagg B., and Stahel R.A. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 51 2 (1992) 296-301
25. Adachi Y., Aoki C., Yoshio-Hoshino N., Takayama K., Curiel D.T., and Nishimoto N. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 119 6 (2006) 1303-1311